Hagn, G., Meier-Menches, S. M., Plessl-Walder, G., Mitra, G., Mohr, T., Preindl, K., Schlatter, A., Schmidl, D., Gerner, C., Garhöfer, G., & Bileck, A. (2024). Plasma Instead of Serum Avoids Critical Confounding of Clinical Metabolomics Studies by Platelets. Journal of Proteome Research, 23(8), 3064-3075. https://doi.org/10.1021/acs.jproteome.3c00761

Wimmer, B., Schernthaner, J., Edobor, G., Friedrich, A., Poeltner, K., Temaj, G., Wimmer, M., Kronsteiner, E., Pichler, M., Gercke, H., Huber, R., Kaefer, N., Rinnerthaler, M., Karl, T., Krauß, J., Mohr, T., Gerner, C., Hintner, H., Breitenbach, M., ... Breitenbach-Koller, H. (2024). RiboScreen^TM Technology Delivers a Ribosomal Target and a Small-Molecule Ligand for Ribosome Editing to Boost the Production Levels of Tropoelastin, the Monomeric Unit of Elastin. International Journal of Molecular Sciences, 25(15), Article 8430. https://doi.org/10.3390/ijms25158430

Skos, L., Schmidt, C., Thomas, S. R., Park, M., Geiger, V., Wenisch, D., Bonsignore, R., Del Favero, G., Mohr, T., Bileck, A., Gerner, C., Casini, A., & Meier-Menches, S. M. (2024). Gold-templated covalent targeting of the CysSec-dyad of thioredoxin reductase 1 in cancer cells. Cell Reports Physical Science, 5(7), Article 102072. https://doi.org/10.1016/j.xcrp.2024.102072

Janker-Bortel, P., Hagn, G., Skos, L., Bileck, A., Paulitschke, V., Paulitschke, P., Gleiter, L., Mohr, T., Gerner, C., & Meier-Menches, S. M. (2024). Memory effects of prior subculture may impact the quality of multiomic perturbation profiles. Proceedings of the National Academy of Sciences of the United States of America, 121(29), Article e2313851121. https://doi.org/10.1073/pnas.2313851121

Zila, N., Eichhoff, O. M., Steiner, I., Mohr, T., Bileck, A., Cheng, P. F., Leitner, A., Gillet, L., Sajic, T., Goetze, S., Friedrich, B., Janker-Bortel, P., Strobl, J., Reitermaier, R., Hogan, S. A., Martínez Gómez, J. M., Staeger, R., Tuchmann, F., Peters, S., ... Paulitschke, V. (2024). Proteomic Profiling of Advanced Melanoma Patients to Predict Therapeutic Response to Anti-PD-1 Therapy. Clinical Cancer Research, 30(1), 159-175. https://doi.org/10.1158/1078-0432.CCR-23-0562

Ries, A., Flehberger, D., Slany, A., Pirker, C., Mader, J. C., Mohr, T., Schelch, K., Sinn, K., Mosleh, B., Hoda, M. A., Dome, B., Dolznig, H., Krupitza, G., Müllauer, L., Gerner, C., Berger, W., & Grusch, M. (2023). Mesothelioma-associated fibroblasts enhance proliferation and migration of pleural mesothelioma cells via c-Met/PI3K and WNT signaling but do not protect against cisplatin. Journal of Experimental and Clinical Cancer Research, 42(1), Article 27. https://doi.org/10.1186/s13046-022-02582-0

Baier, D., Mendrina, T., Schoenhacker-Alte, B., Pirker, C., Mohr, T., Rusz, M., Regner, B., Schaier, M., Sgarioto, N., Raynal, N. J. M., Nowikovsky, K., Schmidt, W. M., Heffeter, P., Meier-Menches, S. M., Koellensperger, G., Keppler, B. K., & Berger, W. (2023). The Lipid Metabolism as Target and Modulator of BOLD-100 Anticancer Activity: Crosstalk with Histone Acetylation. Advanced science, 10(32), Article 2301939. https://doi.org/10.1002/advs.202301939

Mödl, B., Awad, M., Zwolanek, D., Scharf, I., Schwertner, K., Milovanovic, D., Moser, D., Schmidt, K., Pjevac, P., Hausmann, B., Krauß, D., Mohr, T., Svinka, J., Kenner, L., Casanova, E., Timelthaler, G., Sibilia, M., Krieger, S., & Eferl, R. (2023). Defects in microvillus crosslinking sensitize to colitis and inflammatory bowel disease. EMBO Reports, 24(10), Article e57084. https://doi.org/10.15252/embr.202357084

Janker, L., Schuster, D., Bortel, P., Hagn, G., Meier-Menches, S. M., Mohr, T., Mader, J. C., Slany, A., Bileck, A., Brunmair, J., Madl, C., Unger, L., Hennlich, B., Weitmayr, B., Del Favero, G., Pils, D., Pukrop, T., Pfisterer, N., Feichtenschlager, T., & Gerner, C. (2023). Multi-omics empowered deep phenotyping of ulcerative colitis identifies biomarker signatures reporting functional remission states. Journal of Crohn's & colitis, 17(9), 1514-1527. https://doi.org/10.1093/ecco-jcc/jjad052

Ries, A., Slany, A., Pirker, C., Mader, J. C., Mejri, D., Mohr, T., Schelch, K., Flehberger, D., Maach, N., Hashim, M., Hoda, M. A., Dome, B., Krupitza, G., Berger, W., Gerner, C., Holzmann, K., & Grusch, M. (2023). Primary and hTERT-Transduced Mesothelioma-Associated Fibroblasts but Not Primary or hTERT-Transduced Mesothelial Cells Stimulate Growth of Human Mesothelioma Cells. Cells, 12(15), Article 2006. https://doi.org/10.3390/cells12152006

Caban, M., Koblmueller, B., Groza, D., Schueffl, H. H., Terenzi, A., Tolios, A., Mohr, T., Mathuber, M., Kryeziu, K., Jaunecker, C., Pirker, C., Keppler, B. K., Berger, W., Kowol, C. R., & Heffeter, P. (2023). A novel EGFR inhibitor acts as potent tool for hypoxia-activated prodrug systems and exerts strong synergistic activity with VEGFR inhibition in vitro and in vivo. Cancer Letters, 565, Article 216237. https://doi.org/10.1016/j.canlet.2023.216237

Soukup, R., Gerner, I., Mohr, T., Gueltekin, S., Grillari, J., & Jenner, F. (2023). Mesenchymal Stem Cell Conditioned Medium Modulates Inflammation in Tenocytes: Complete Conditioned Medium Has Superior Therapeutic Efficacy than Its Extracellular Vesicle Fraction. International Journal of Molecular Sciences, 24(13), Article 10857. https://doi.org/10.3390/ijms241310857

Ertl, I. E., Brettner, R., Kronabitter, H., Mohr, T., Derdak, S., Jeitler, M., Bilban, M., Garstka, N., & Shariat, S. F. (2023). The SMARCD Family of SWI/SNF Accessory Proteins Is Involved in the Transcriptional Regulation of Androgen Receptor-Driven Genes and Plays a Role in Various Essential Processes of Prostate Cancer. Cells, 12(1), Article 124. https://doi.org/10.3390/cells12010124

Malik, B., Vokic, I., Mohr, T., Poppelaars, M., Holcmann, M., Novoszel, P., Timelthaler, G., Lendl, T., Krauss, D., Elling, U., Mildner, M., Penninger, J. M., Petzelbauer, P., Sibilia, M., & Csiszar, A. (2023). FAM3C/ILEI protein is elevated in psoriatic lesions and triggers psoriasiform hyperproliferation in mice. EMBO Molecular Medicine, 15(7), Article e16758. https://doi.org/10.15252/emmm.202216758

Moritsch, S., Moedl, B., Scharf, I., Janker, L., Zwolanek, D., Timelthaler, G., Casanova, E., Sibilia, M., Mohr, T., Kenner, L., Herndler-Brandstetter, D., Gerner, C., Mueller, M., Strobl, B., & Eferl, R. (2022). Tyk2 is a tumor suppressor in colorectal cancer. OncoImmunology, 11(1), Article 2127271. https://doi.org/10.1080/2162402X.2022.2127271